Sanigen Co

Sanigen Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanigen Co (188260.KQ) as of Oct 20, 2026 is -5.69 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.47 B KRW — a change of 27.35% (lower).

EBITDA

-5.69 BKRW

YoY

27.35%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanigen Co is 2025 -5.69 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanigen Co was 2024 -4.47 B KRW. It decreases by 27.35% lower compared to the previous year.

The Sanigen Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-484.45 M KRW
Jan 1, 2020
-1.67 B KRW
Jan 1, 2022
-3.48 B KRW
Jan 1, 2023
-7.90 B KRW
Jan 1, 2024
-4.47 B KRW
Jan 1, 2025
-5.69 B KRW
The Sanigen Co EBITDA history
YEAREBITDAYoY
-5.69 BKRW+27.35%
-4.47 BKRW-43.46%
-7.90 BKRW+127.26%
-3.48 BKRW+108.56%
-1.67 BKRW+244.02%
-484.45 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sanigen Co Stock analysis

What does Sanigen Co do? Sanigen Co Ltd generates revenue through the manufacturing and sale of food safety diagnostic products, utilizing advanced molecular diagnostic technologies including polymerase chain reaction (PCR) and next-generation sequencing (NGS). The company provides food microbial genome analysis services as part of its offerings. Its primary customers are entities requiring food safety testing, such as food manufacturers and regulatory agencies. The firm operates within the Health Care Equipment & Supplies industry, focusing on diagnostic solutions for food safety. Sanigen Co Ltd's product portfolio includes diagnostic products developed using PCR and NGS technologies, which are sold to clients in the food safety sector. The company's services encompass microbial genome analysis, targeting clients needing detailed food safety assessments. The business model centers on delivering diagnostic tools and services that ensure food safety through advanced molecular technologies. The company's revenue streams are derived from the sale of diagnostic products and the provision of microbial genome analysis services. These offerings are tailored to meet the needs of food safety testing in the industry. Sanigen Co Ltd's focus on molecular diagnostic technologies positions it as a provider of specialized solutions within the health care equipment and supplies market. Sanigen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sanigen Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanigen Co is -5.69 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sanigen Co changed from -4.47 B KRW to -5.69 B KRW, representing a 27.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sanigen Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sanigen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sanigen Co

All Key Metrics — Sanigen Co